The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer.
immunotherapy
resectable nonsmall cell lung cancer
targeted therapy
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
14
11
2022
received:
07
11
2022
accepted:
18
11
2022
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
ppublish
Résumé
As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-281Subventions
Organisme : Mason Family Philanthropic Research Fund
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554.
Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current surgical indications for non-small-cell lung cancer. Cancers. 2022;14(5):1263.
Shu CA, Cascone T. What is neo? Chemoimmunotherapy in the neoadjuvant setting for resectable non-small-cell lung cancer. J Clin Oncol. 2021;39(26):2855-2858.
Anderson MD, Cancer Center. LCRF leader neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early stage lung cancers. PI: Boris Sepesi. Est Completion. 2023:NCT04712877.
Steuer CE, Behera M, Berry L, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the lung cancer mutation consortium. Cancer. 2016;122(5):766-772.
Kim D-W, Gadgeel SM, Gettinger SN, et al. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). J Clin Oncol. 2018;36(suppl 15):9009.
NCCN. Clinical practice guidelines in oncology. Non-small cell lung cancer. 2022.
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973-1985.
FDA. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. 2022.
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357.
FDA. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer
O'Brien MER, Paz-Ares L, Jha N, et al. EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. J Clin Oncol. 2022;40(suppl 16):8512.
Paz-Ares L, O'Brien MER, Mauer M, et al. VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study. Ann Oncol. 2022;33(4):451-453.
Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(suppl 18):LBA5.
Wu Y-L, John T, Grohe C, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol. 2022;17(3):423-433.
Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1723.
Heymach JV, Mitsudomi T, Harpole D, et al. Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN trial. Clin Lung Cancer. 2022;23(3):247.
Fernando HC, Yang J, Ferraro GL, Keller SM. Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671. J Clin Oncol. 2018;36(suppl 15):TPS8583.
Cascone T, Provencio M, Sepesi B, et al. Checkmate 77T: a phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC. J Clin Oncol. 2020;38(suppl 15):TPS9076.
Peters S, Kim AW, Solomon B, et al. IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Ann Oncol. 2019;30:ii30.
Melillo G, Chand V, Yovine A, Gupta A, Massacesi C. Curative-intent treatment with durvalumab in early-stage cancers. Adv Ther. 2021;38(6):2759-2778.
Chaft JE, Dahlberg SE, Khullar OV, et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). J Clin Oncol. 2018;36(suppl 15):TPS8581.
Peters S, Spigel D, Ahn M, et al. P03.03 MERMAID-1: a phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery. J Thorac Oncol. 2021;16(3):S258-S259.
Spigel DR, Peters S, Ahn MJ, et al. 93TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. J Thorac Oncol. 2021;16(4):S745-S746.
Tsuboi M, Weder W, Escriu C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021;17(31):4045-4055.
Lee JayM, B, S, Toloza EricM, Lin Jules, et al. Phase II NAUTIKA1 study of targeted therapies in stage II-III NSCLC: preliminary data of neoadjuvant Alectinib for ALK+ NSCLC. 2022.
Skoulidis F. A phase ii study of neoadjuvant sotorasib in combination with cisplatin or carboplatin and pemetrexed for surgically resectable stage IIA-IIIB non-squamous non-small cell lung cancer with a KRAS p.G12C mutation: NCT05118854. 2022.
Lee JM, Awad MM, Saliba TR, Caro N, Banerjee H, Kelly K. Neoadjuvant and adjuvant capmatinib in resectable non-small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial. J Clin Oncol. 2022;40(suppl 16):TPS8590.
Goldman JW, Tsutani Y, He Jie. A global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 NSCLC following complete tumour resection (ADAURA2), (NCT05120349). https://clinicaltrials.gov/ct2/show/NCT05120349
Chaft JE, Dahlberg SE, Gerber DE, et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): the newest study in the ALCHEMIST platform. J Clin Oncol. 2017;35(suppl 15):TPS8575.
Sepesi B, Jones DR, Meyers BF, et al. LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers. J Clin Oncol. 2022;40(suppl 16):TPS8596.
Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events during anticancer immunotherapy: pathogenesis and management. Oncol Lett. 2017;14(5):5671-5680.
Blidner AG, Choi J, Cooksley T, et al. Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer. 2020;28(12):6111-6117.
Ni J, Huang M, Zhang L, et al. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thorac Cancer. 2021;12(9):1469-1488.
ctDNA guiding treatment after almonertinib induction therapy for EGFRm+ NSCLC in the MDT diagnostic model (APPROACH). 2021. https://clinicaltrials.gov/ct2/show/NCT04841811